Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics
HBIO Price/Volume Stats
Current price | $4.24 | 52-week high | $6.29 |
Prev. close | $4.20 | 52-week low | $3.45 |
Day low | $4.17 | Volume | 93,670 |
Day high | $4.31 | Avg. volume | 81,908 |
50-day MA | $4.42 | Dividend yield | N/A |
200-day MA | $4.62 | Market Cap | 184.01M |
HBIO Stock Price Chart Interactive Chart >
HBIO POWR Grades
- HBIO scores best on the Growth dimension, with a Growth rank ahead of 97.44% of US stocks.
- HBIO's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- HBIO ranks lowest in Momentum; there it ranks in the 24th percentile.
HBIO Stock Summary
- HARVARD BIOSCIENCE INC's market capitalization of $212,160,583 is ahead of 27.01% of US-listed equities.
- With a year-over-year growth in debt of -20.43%, HARVARD BIOSCIENCE INC's debt growth rate surpasses merely 15.84% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, HARVARD BIOSCIENCE INC is reporting a growth rate of -126.36%; that's higher than merely 10.72% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to HARVARD BIOSCIENCE INC are KVHI, ICHR, OMCL, EXAS, and SWI.
- HBIO's SEC filings can be seen here. And to visit HARVARD BIOSCIENCE INC's official web site, go to www.harvardbioscience.com.
HBIO Valuation Summary
- In comparison to the median Healthcare stock, HBIO's price/sales ratio is 52.38% lower, now standing at 2.
- Over the past 243 months, HBIO's price/earnings ratio has gone down 258.6.
Below are key valuation metrics over time for HBIO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
HBIO | 2023-12-29 | 2.0 | 3.1 | -70.0 | 198.4 |
HBIO | 2023-12-28 | 2.1 | 3.1 | -70.8 | 200.3 |
HBIO | 2023-12-27 | 2.1 | 3.2 | -71.8 | 202.9 |
HBIO | 2023-12-26 | 2.0 | 3.1 | -70.5 | 199.7 |
HBIO | 2023-12-22 | 2.0 | 3.1 | -70.6 | 200.0 |
HBIO | 2023-12-21 | 2.0 | 3.0 | -69.1 | 196.2 |
HBIO Growth Metrics
- The 5 year net cashflow from operations growth rate now stands at 61.96%.
- The 2 year net cashflow from operations growth rate now stands at -119.77%.
- The 3 year net income to common stockholders growth rate now stands at -429.23%.
The table below shows HBIO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 117.963 | -1.41 | -6.889 |
2022-06-30 | 120.704 | -2.719 | -3.654 |
2022-03-31 | 120.693 | -1.761 | -6.499 |
2021-12-31 | 118.904 | 1.262 | -0.288 |
2021-09-30 | 116.833 | 3.635 | -1.864 |
2021-06-30 | 111.207 | 5.892 | -2.792 |
HBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HBIO has a Quality Grade of C, ranking ahead of 42.11% of graded US stocks.
- HBIO's asset turnover comes in at 0.728 -- ranking 27th of 75 Measuring and Control Equipment stocks.
- CAMT, NVMI, and ITRI are the stocks whose asset turnover ratios are most correlated with HBIO.
The table below shows HBIO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.728 | 0.566 | -0.002 |
2021-03-31 | 0.693 | 0.574 | 0.005 |
2020-12-31 | 0.666 | 0.568 | -0.027 |
2020-12-31 | 0.666 | 0.568 | -0.027 |
2020-09-30 | 0.657 | 0.564 | -0.018 |
2020-06-30 | 0.665 | 0.560 | -0.029 |
HBIO Price Target
For more insight on analysts targets of HBIO, see our HBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $10.00 | Average Broker Recommendation | 1.38 (Strong Buy) |
Harvard Bioscience, Inc. (HBIO) Company Bio
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.
Latest HBIO News From Around the Web
Below are the latest news stories about HARVARD BIOSCIENCE INC that investors may wish to consider to help them evaluate HBIO as an investment opportunity.
Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Jim Green, Chairman and Chief Executi |
With 60% ownership, Harvard Bioscience, Inc. (NASDAQ:HBIO) boasts of strong institutional backingKey Insights Significantly high institutional ownership implies Harvard Bioscience's stock price is sensitive to their... |
Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer. The Company’s presentation will begin at 9:40 AM ET / 8:40 AM CT on November 16th. A replay of the presentation will be |
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2023 Earnings Call TranscriptHarvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2023 Earnings Call Transcript November 7, 2023 Harvard Bioscience, Inc. misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.04. Operator: Thank you for standing by and welcome to the Harvard Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today’s program is being recorded. […] |
Q3 2023 Harvard Bioscience Inc Earnings CallQ3 2023 Harvard Bioscience Inc Earnings Call |
HBIO Price Returns
1-mo | -4.07% |
3-mo | -20.75% |
6-mo | -1.40% |
1-year | 8.16% |
3-year | -21.34% |
5-year | -1.62% |
YTD | -20.75% |
2023 | 93.14% |
2022 | -60.71% |
2021 | 64.34% |
2020 | 40.66% |
2019 | -4.09% |
Continue Researching HBIO
Want to see what other sources are saying about Harvard Bioscience Inc's financials and stock price? Try the links below:Harvard Bioscience Inc (HBIO) Stock Price | Nasdaq
Harvard Bioscience Inc (HBIO) Stock Quote, History and News - Yahoo Finance
Harvard Bioscience Inc (HBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...